

INDEX

I-1

	<u>page(s)</u>
".8" and Primary Site Code	73
".9" and Primary Site Code	73, 74
abbreviations, acceptable	Appendix C
abbreviations for City/Town at Diagnosis	56
Abstract, paper, Massachusetts Cancer Registry	4, 5, 6
Abstracted By	47
Abstracted By as new field.....	ii
abstractor of case	47
"abuts" and Summary Stage	127
Accession Number	41
Accession Number and diagnosis year	41
Accession Number and Year First Seen for This Primary	45
Accession Number as new field.....	ii
Address at Diagnosis	55-58
Address at Diagnosis and nonanalytic case reporting.....	10
address, for college student	55
address, foreign.....	56-58
address, military base.....	55
adenocarcinoma in adenomatous polyposis coli	14-15
adenocarcinoma in multiple adenomatous polyps.....	14-15
"adherent" and Summary Stage	127
adjuvant chemotherapy	162
Admission Date	47
Admission Date used as Discharge Date	47
Age at Diagnosis	53
Age at Diagnosis and nonanalytic case reporting.....	10
Age , patient's	53
age/diagnosis combination, unusual, and Comments	176
AJCC staging	102-124
AJCC staging books as references	8
"aka" name.....	51
Alias	51
Alias as new field.....	ii
"also known as" name.....	51
analytic case and Class of Case	92
ancillary drug.....	172
ancillary drug and Chemotherapy -- Narrative	163, 165
ancillary drugs	163
ancillary drugs, types of	172
antihormone therapy.....	166-169
"apparently" and case reportability.....	12
"apparently" and Summary Stage	127

INDEX

I-2

	<u>page(s)</u>
Approach, Surgical	147-148, Appendix D
"approaching" and case reportability	12
"approaching" and Summary Stage	127
"areas of" and Histologic Type Code	81
aspiration of cells and non cancer-directed surgery.....	144
aspiration of node and Scope of Regional Lymph Node Surgery	153
aspiration, bone marrow, and Confirmation Method	99
aspiration, fine needle, and Confirmation Method	99
"assisted by endoscopy" and open Surgical Approach	148
at this facility, treatment, fields	143
aTNM	102
autopsy biopsy and Confirmation Method	99
autopsy, cancer found at.....	3
autopsy case and Admission Date	47
autopsy case and Date of Diagnosis	90
autopsy case and Discharge Date	47
autopsy case and Reason for No Cancer-Directed Surgery	157
autopsy case and treatment dates	143
autopsy, gross and Confirmation Method	100
autopsy prefix and TNM staging, not coded	102
"autumn" and Date of Diagnosis	91
basal cell carcinomas, as non-reportable cases	11, 83
beam radiation, types of	159
behavior and Histologic Type Code	80-82
behavior and single-vs-multiple primaries.....	15, 17
Behavior Code	83-86
Behavior Code and case reportability	11, 83
Behavior Code and nonanalytic case reporting.....	10
benign cases, reportability	11, 83
benign tumor, Sequence Number	42, 44
bilateral involvement and single-vs-multiple primaries.....	18
bilateral lymph node involvement and Summary Stage	131
bilateral ovarian primary, Laterality	75
bilateral retinoblastoma, Laterality	75
bilateral tumors and TNM staging	102
biological response modifier therapy.....	169-171
biopsy and Confirmation Method	99
biopsy, bone marrow, and Confirmation Method	99
biopsy, excisional, and cancer-directed surgery	147
biopsy, excisional and Tumor Size	94
biopsy, incisional, and non cancer-directed surgery	144
biopsy, negative and positive cytology, case reportability	40

INDEX

I-3

	<u>page(s)</u>
biopsy, NOS and non cancer-directed surgery	144
Birth Date	52
Birth Date and changes/case deletion	5
Birth Date and nonanalytic case reporting	10
Birthplace	54, Appendix A
Birthplace and Race	60
Birthplace and Spanish/Hispanic Origin	62
bladder cases, and single-vs-multiple primaries	17
bladder, transurethral resection and Tumor Size	98
Bloom-Richardson grading and Grade Code	89
bone marrow aspiration and Confirmation Method	99
bone marrow biopsy and Confirmation Method	99
borderline malignancy, and Sequence Number	42, 44
borderline malignancy, case reportability	11, 83
Bowen's disease and Behavior Code	85
Bowen's disease and Summary Stage	128
BR grading and Grade Code	89
brachytherapy, radioactive implants	160
brain primary and Regional Nodes Examined	136
brain primary and Regional Nodes Positive	136
brain tumor and Grade Code	88
brain tumors, reportability	11, 83
breast cancer and Grade Code	89
breast cancer and Tumor Size	97
breast cancer cases and single-vs-multiple primaries	19
BRM therapy	169-171
business/industry	68-71
bypass and non cancer-directed surgery	144
cancer-directed surgery	147-157, Appendix D
cancer-directed surgery and endocrine surgery	167
cancer-directed surgery and radiation therapy	161
cancer-directed surgery, none, and TNM staging	103
"cancer-directed treatment" defined	142
carcinoma <i>in situ</i> of cervix uteri, case reportability	11, 83
carcinoma, inflammatory, and Tumor Size	97
carcinoma, squamous cell, microinvasive, and Behavior Code	86
carcinoma, squamous cell, microinvasive, and Summary Stage	129
carcinomas, basal cell, as non-reportable cases	11, 83
carcinomas, ductal and lobular, and Primary Site Code	75
carcinomas, papillary, of skin C44._, as non-reportable cases	11, 83
carcinomas, squamous cell, of skin C44._, as non-reportable cases	11, 83
Case Completed, Date	177

INDEX

I-4

	<u>page(s)</u>
Case Exported, Date	177
Case Report Exported, Date	177
case submission to the Massachusetts Cancer Registry.....	4
casefinding.....	3
CDC grant to Massachusetts Cancer Registry.....	1
cell aspiration and non cancer-directed surgery.....	144
Cell Origin Code	86-89
cell type origin and differentiation.....	87
Cell Type Origin Code	86-89
central nervous system cases, reportability.....	11, 83
cervical intraepithelial neoplasia, case reportability.....	11, 83
cervix uteri, carcinoma <i>in situ</i> , case reportability.....	11, 83
cervix, intraepithelial neoplasia of, case reportability.....	11, 83
Change/Delete form, Massachusetts Cancer Registry.....	4, 5, 7
changes, electronic.....	5
changes to reported cases.....	4, 5
charity case, Primary Payer at Diagnosis	46
chemotherapy.....	162-165
chemotherapy, adjuvant.....	162
chemotherapy agents.....	163
Chemotherapy -- At This Facility	164
Chemotherapy -- At This Facility having new codes.....	v
Chemotherapy -- Date Started	165
chemotherapy drugs.....	163
Chemotherapy -- Narrative	165
Chemotherapy -- Narrative and ancillary drug.....	163, 165
chemotherapy protocol number.....	162, 165
Chemotherapy -- Summary	164
Chemotherapy -- Summary having new codes.....	v
chemotherapy with Prednisone.....	166
child, recording occupation/industry for.....	69
CIN III, case reportability.....	11, 83
City at Diagnosis	56
City/Town at Diagnosis	56
Class 3 case and Address at Diagnosis	55
Class 3 case and Summary Stage	125, 132
Class 3 case and Summary Stage	131
Class 3 case reporting.....	10
Class 4 case and Address at Diagnosis	55
Class 4 case and Summary Stage	125, 132
Class 4 case and Summary Stage	131
Class 4 case reporting.....	10

INDEX

I-5

	<u>page(s)</u>
Class 5 case and Date of Diagnosis	90
Class 5 case reporting	10
Class 6 cases, reportability	40
Class 9 case reporting	10
Class of Case	92-93
Class of Case and Case 6's.....	iii
Class of Case and reportability	40
clinical M Element	109-111
clinical N Element.....	107-108
clinical Stage Grouping.....	112-113
clinical staging, TNM	102-113
clinical T Element.....	104-106
clinical trial, double-blind, therapy.....	172
clitoris, skin of, case reportability	11, 83
cM	109-111
cM88	109, 111
cMX.....	109, 111
cN	107-108
cN88.....	108
cNX	107, 108
code priority, surgery of primary site.....	149
coding pre-1998 cases.....	i
colon cancer and Tumor Size	97
colon polyps and single-vs-multiple primaries.....	14-15
combination codes, histology.....	19, 80-81
combination histology codes.....	19, 80-81
combination, site/histology, and Comments	176
Comments/Narrative Remarks	176
Comments/Narrative Remarks and previous primaries.....	43
Comments/Narrative Remarks for changes and case deletion.....	5
<i>Comparative Staging Guide for Cancer</i> as reference	9
"compatible with" and case reportability.....	12
"compatible with" and Summary Stage	127
computer vendor, name.....	177
confidentiality	2
Confirmation Method	99-100
confirmation of diagnosis, and case reportability.....	11
confirmation, pathologic, and case reportability	11
conization and Confirmation Method	99
"consistent with" and case reportability	12
"consistent with" and Summary Stage	127
consultation-only cases, reportability	40
COPP + Prednisone	166

INDEX

I-6

	<u>page(s)</u>
cStage Grouping.....	112-113
cStage Grouping 88.....	112, 113
cStage Grouping 99.....	112, 113
cT.....	104-106
CT scan and Confirmation Method	100
cT88.....	105
cTNM.....	102-113
cTX.....	105, 106
curettage and Confirmation Method	99
cystadenoma, ovarian and Behavior Code	84
cytology and Confirmation Method	99
cytology report and Grade/Differentiation/Cell Origin Code	86
cytology report and negative biopsy, case reportability.....	40
cytology report, "suspicious", and case reportability.....	12
D&C and non cancer-directed surgery.....	144
data set collected by Massachusetts Cancer Registry.....	1, 10
<i>Data Standards</i> , NAACCR, as reference.....	9
Date Case Completed	177
Date Case Completed as new field.....	vi
Date Case Report Exported	177
Date Case Report Exported as new field.....	vi
date of admission.....	47
Date of Birth	52
date of death and Date of Diagnosis for autopsy case.....	90
date of death as Admission Date	47
date of death as Date of Last Contact	175
Date of Diagnosis	90-91
Date of Diagnosis and changes/case deletion.....	5
Date of Diagnosis and nonanalytic case reporting.....	10
Date, Chemotherapy Started	165
date of discharge.....	47
Date, Hormone Therapy Started	168
Date, Immunotherapy Started	171
Date, Non Cancer-Directed Surgery Started	146
Date of Last Contact	175
Date of Last Contact and nonanalytic case reporting.....	10
Date, Other Therapy Started	174
Date, Radiation Therapy Started	161
Date, Surgery of Primary Site Started	151
dates, treatment started.....	143
death date and Date of Diagnosis for autopsy case.....	90
death date as Admission Date for autopsy case.....	47

INDEX

I-7

	<u>page(s)</u>
death date as Date of Last Contact	175
Death, Place of	176, Appendix A
"default" Primary Site Code	74
deleting a reported case	4, 5
diagnosis/age combination, unusual, and Comments	176
Diagnosis Date	90-91
diagnosis year and Age at Diagnosis	53
Diagnostic Confirmation	99-100
differentiation and cell type origin	87
Differentiation Code	86-89
"diffuse" and Tumor Size	97
dilation and curettage, and non cancer-directed surgery	144
"direct extension" and Summary Stage	126
direct visualization and Confirmation Method	100
Discharge Date	47
Discharge Date as Date of Last Contact	175
Discharge Date for autopsy case.....	47
diskette, reporting cases on	4, 5, 41, 49
dissection, neck, and Scope of Regional Lymph Node Surgery	153
distant Summary Stage	131
double-blind clinical trial therapy.....	172
drug, ancillary.....	163, 172
drug, chemotherapy.....	163
drug, immunotherapy.....	169
ductal and lobular carcinomas of breast.....	19
ductal and lobular carcinomas of breast, and Primary Site Code	75
"E", lymphoma suffix, and TNM staging, not collected.....	113, 123
"E+S", lymphoma suffix, and TNM staging, not collected.....	113, 123
"elements of" and Histologic Type Code	81
Elston-Ellis grading and Grade Code	89
embolization, tumor	172
employer	68-71
en bloc resection of primary and regional tissues, and surgery of primary site	149, 155
"encroaching upon" and Summary Stage	127
endocrine gland removal and non cancer-directed surgery	144
endocrine radiation	166, 167
endocrine surgery	166, 167
endocrine surgery and cancer-directed surgery.....	167
endocrine therapy.....	166-169
endoscopy and Confirmation Method	100
endoscopy, assisted by, and open Surgical Approach	148
"endoscopy, image-guided" and Surgical Approach	147

INDEX

I-8

	<u>page(s)</u>
"enlarged", lymph nodes, and Summary Stage	132
epithelial carcinomas of skin C44., as non-reportable cases	11, 83
"equivocal" and case reportability	12
"equivocal" and Summary Stage	127
erythroplasia, Queyrat's, and Behavior Code	85
erythroplasia, Queyrat's, and Summary Stage	128
esophagus, cancer of, and Tumor Size	97
estimating Birth Date	52
estimating Date of Diagnosis	91
ethnicity and Spanish/Hispanic Origin	62
excisional biopsy and cancer-directed surgery	147
excisional biopsy and Tumor Size	94
exploratory and non cancer-directed surgery	144
Exported Date, of Case	177
"extension into" and Summary Stage	127
"extension onto" and Summary Stage	127
"extension out onto" and Summary Stage	127
"extension to" and Summary Stage	127
extralymphatic involvement, lymphoma, and TNM staging	113, 123
Facility Code	41
Facility Code and diskette reporting	41
Facility Name	41
Facility Name and diskette reporting.....	41
failed treatment	142
"fall" and Date of Diagnosis	91
familial polyposis and Primary Site Code	75
familial polyposis and Tumor Size	97
familial polyposis, colon polyps, and single-vs-multiple primaries	14-15
"favors" and case reportability	12
"favors" and Summary Stage	127
fine needle aspiration and Confirmation Method	99
first course of therapy and Regional Nodes Examined	135
first course of therapy and Regional Nodes Positive	137
"first course of therapy" defined.....	141-142
first course of treatment and time period.....	141, 142
"first course of treatment" defined.....	141-142
First Name, Patient	50
"fixation" and Summary Stage	127
"fixed" and Summary Stage	127
"fixed", lymph nodes, and Summary Stage	132
Fletcher after-loader, radiation therapy	159
Fletcher suit, radiation therapy.....	159

INDEX

I-9

	<u>page(s)</u>
fluid removal, malignant, and non cancer-directed surgery	144
FNA and Confirmation Method	99
follow-up and Date of Last Contact	175
foreign address.....	56-58
frozen section and Confirmation Method	99
gender, patient's	59
generation identifiers (Junior, Senior, III)	49
genital sites, skin of, case reportability.....	11, 83
gland, endocrine, removal, and non cancer-directed surgery	144
Gleason's Pattern and Grade Code	89
Gleason's Score and Grade Code	89
Grade Code	86-89
Grade Code and nonanalytic case reporting	10
Grade/Differentiation/Cell Origin and new code.....	iii
hematopoietic diseases and single-vs-multiple primaries.....	20-39
hematopoietic neoplasm and Tumor Size	98
Heyman capsule, radiation therapy.....	159
"high grade" lymphoma and Grade Code	87
Hispanic Origin	62-66
Hispanic surname.....	62-66
Histologic Type Code	79-82
Histologic Type Code and nonanalytic case reporting	10
"histologic type difference" for single-vs-multiple primaries.....	15
Histology and case reportability.....	11, 83
histology code, "NOS"	80-82
histology codes, combination.....	19
histology codes, combination.....	80-81
Histology Type Code and new ICD-O codes.....	iii
Histology/Behavior/Grade Narrative	90
histology/site combination, unusual, and Comments	176
HMO, Primary Payer at Diagnosis	46
Hodgkin's disease and Tumor Size	98
homeless patient, address	55
hormonal radiation.....	158
hormonal radiation therapy (endocrine radiation)	166, 167
hormonal surgery (endocrine surgery).....	166, 167
hormone replacement.....	167
hormone therapy	166-169
Hormone Therapy -- At This Facility	168
Hormone Therapy -- At This Facility and new code definitions.....	v
Hormone Therapy -- Date Started	168
Hormone Therapy -- Narrative	168

INDEX

I-10

	<u>page(s)</u>
Hormone Therapy -- Summary	168
Hormone Therapy -- Summary and new code definitions	v
Hutchinson's melanotic freckle and Behavior Code	85
Hutchinson's melanotic freckle and Summary Stage	128
hyperbaric oxygen	172
hyperthermia as "other" therapy.....	172
ICD-O-1 coding book as reference.....	8
ICD-O-2 codes (histology) added since 1995	iii, 20, 79
ICD-O-2 coding book as reference.....	8
ICD-O-2 Primary Site Code	73-75
"III", etc. as generation identifiers	49
ill-defined primary site and Tumor Size	98
ill-defined primary sites C76.____	74
"image-guided endoscopy" and Surgical Approach	147
imaging and Confirmation Method	100
immunoglobulin, iodine-labeled	159
immunotherapy.....	169-171
Immunotherapy -- At This Facility	170
Immunotherapy -- At This Facility and new codes.....	v
Immunotherapy -- Date Started	171
Immunotherapy -- Narrative	171
Immunotherapy -- Summary	170
Immunotherapy -- Summary and new codes	v
immunotherapy agents	169
immunotherapy drugs.....	169
implants, radioactive.....	159
<i>in situ</i> behavior, terms indicating.....	85
<i>in situ</i> cases, reportability.....	11, 83
<i>in situ</i> lesions and Grade Code	87
<i>in situ</i> Summary Stage , terms indicating.....	128
<i>in situ</i> tumor and TNM staging	102, 115
<i>in utero</i> case and Date of Diagnosis	90
incisional biopsy and non cancer-directed surgery	144
"induration" and Summary Stage	127
industry and occupation	68-71
inflammatory carcinoma and Tumor Size	97
initial, middle, patient's	50
initial, used with a middle name.....	50
inpatient Admission Date	47
insurance, Primary Payer at Diagnosis	46
"intermediate grade" lymphoma and Grade Code	87
interstitial radiation	161

INDEX

I-11

	<u>page(s)</u>
intraductal carcinoma and Paget's disease of breast.....	19
intraepithelial neoplasia, cervical, case reportability.....	11, 83
intraepithelial neoplasia, prostatic and Behavior Code	85
intraepithelial neoplasia, prostatic and Summary Stage	128
intraepithelial neoplasia, prostatic, case reportability.....	11, 83, 85
intraepithelial neoplasia, vaginal, case reportability	11, 83
intraepithelial neoplasia, vulvar, case reportability	11, 83
intraoperative radiation	161
"invasion into" and Summary Stage	127
"invasion onto" and Summary Stage	127
"invasion out onto" and Summary Stage	127
"invasion to" and Summary Stage	127
"invasion" and Summary Stage	126
iodine-labeled immunoglobulin	159
"Jr" as generation identifier	49
"Junior" as generation identifier	49
Kaposi's sarcoma and Tumor Size	98
Kaposi's sarcoma, Primary Site Code	75
Kaposi's sarcoma, single-vs-multiple primaries.....	19
Krebiozen	172
laboratory test and Confirmation Method	100
Laetrile	172
laryngopharynx, Primary Site Code change	iii, 73
Last Contact, Date of	175
Last Name, Patient	49
Laterality	76-77
Laterality and Primary Site Narrative	78
laterality and single-vs-multiple primaries	18
lentigno maligna and Behavior Code	85
lentigno maligna and Summary Stage	128
Letterer-Siwe's disease and Regional Nodes Examined	136
Letterer-Siwe's disease and Regional Nodes Positive	136
Letterer-Siwe's disease and Summary Stage	125, 131
Letterer-Siwe's disease and Tumor Size	98
leukemia and Confirmation Method	99
leukemia and first course of treatment	142
leukemia and Regional Nodes Examined	136
leukemia and Regional Nodes Positive	136
leukemia and single-vs-multiple primaries	20-39
leukemia and Summary Stage	125, 131
leukemia and Tumor Size	98
leukemia, Cell Origin Code	87

INDEX

I-12

	<u>page(s)</u>
leukemia, Primary Site Code	75
linitis plastica and Tumor Size	97
lobular and ductal carcinomas of breast.....	19
lobular and ductal carcinomas of breast, and Primary Site Code	75
lobular neoplasia and Behavior Code	85
lobular neoplasia and Summary Stage	128
localized Summary Stage	129
"low grade" lymphoma and Grade Code	87
low malignant potential, case reportability.....	11, 83
lung cancer and Tumor Size	97
lung cancer, occult, and TNM staging.....	105, 106, 113, 116, 123
lymph node aspiration and Scope of Regional Lymph Node Surgery	153
lymph node, extension of primary tumor into, and TNM staging.....	107, 114, 117
lymph node involvement and Summary Stage	132
Lymph Nodes Removed, Regional, Number of	154
lymph nodes, bilateral involvement, and Summary Stage	131
"lymphadenopathy" and Summary Stage	132
lymphatic diseases and single-vs-multiple primaries.....	20-39
lymphatic invasion and TNM staging, not coded.....	102
lymphoma and Regional Nodes Examined	136
lymphoma and Regional Nodes Positive	136
lymphoma and single-vs-multiple primaries.....	20-39
lymphoma codes added to ICD-O-2 since 1995.....	iii, 20
lymphoma, Cell Origin Code	87
lymphoma, Histologic Type Code	79
lymphoma, Primary Site Code	75
lymphoproliferative malignancy, lymphoreticular process, and Primary Site Code	75
lymphoreticular process malignancy and Primary Site Code	75
macroscopic margin involvement and Surgical Margins	152
magnetic resonance imaging and Confirmation Method	100
magnetic resonance imaging and Grade Code	88
Maiden Name	50
maiden name, Spanish/Hispanic.....	62-66
malignancy, borderline, and Sequence Number	42, 44
malignancy, borderline, case reportability.....	11, 83
malignancy, low potential for, case reportability.....	11, 83
malignancy, uncertain, and Sequence Number	42, 44
malignancy, uncertain, case reportability.....	11, 83
malignant neoplasms, NOS of skin C44.__, as non-reportable cases.....	11, 83
malignant tumor, Sequence Number	42-43
managing physician.....	48
Managing Physician Name	48

INDEX

I-13

	<u>page(s)</u>
Margins, Surgical	152, Appendix D
Marital Status at Diagnosis	59
marker study and Confirmation Method	100
"mass in the mediastinum", lymph nodes, and Summary Stage	132
"mass in the mesentery", lymph nodes, and Summary Stage	132
"mass in the retroperitoneum", lymph nodes, and Summary Stage	132
Massachusetts Cancer Registry data set.....	1
Massachusetts Cancer Registry established	1
Massachusetts Cancer Registry regulations.....	1, 2
Massachusetts Cancer Registry, purposes.....	1
"matted", lymph nodes, and Summary Stage	132
MCR Cancer Patient Abstract (paper form).....	4, 5, 6
MCR Change/Delete form	4, 5, 7
Medicaid, Primary Payer at Diagnosis	46
Medical Record Number	47
Medical Record Number and nonanalytic case reporting	10
Medicare claim number	54
Medicare, Primary Payer at Diagnosis	46
melanoma and Tumor Size	97
melanoma of skin and "site differences"	14
melanoma, Primary Site Code	75
melanosis, precancerous, and Behavior Code	85
melanosis, precancerous, and Summary Stage	128
meninges cases, reportability.....	11, 83
"metastasis" and Summary Stage	126
metastatic lesions, vs. primary.....	12
metastatic site and Behavior Code	84
metastatic site and Confirmation Method	99
metastatic site and Grade/Differentiation/Cell Origin Code	86
metastatic sites and Narrative Staging	111, 121
metastatic sites and TNM staging, not coded.....	111, 121
metastatic Summary Stage	131
metastatic-vs-primary site.....	74, 78
"microinvasion" and Summary Stage	126
"microinvasive" and Behavior Code	86
microinvasive squamous cell carcinoma and Behavior Code	86
microinvasive squamous cell carcinoma and Summary Stage	129
"microinvasive" and Summary Stage	129
microscopic confirmation and Confirmation Method	99
microscopic margin involvement and Surgical Margins	152
middle initial, patient.....	50
middle name and first initial	50

INDEX

I-14

	<u>page(s)</u>
Middle Name changed from initial.....	ii
Middle Name, Patient	50
"middle of year" and Date of Diagnosis	91
midline tumor and Laterality	75
midline tumor and Summary Stage	131
MOPP + Prednisone.....	166
"most likely" and case reportability.....	12
"most likely" and Summary Stage	127
MRI and Confirmation Method	100
MRI results and Grade Code	88
multicentric tumors and Summary Stage	129
multimodality therapy prefix and TNM staging, not coded.....	103
multiple myeloma and Confirmation Method	100
multiple myeloma and Regional Nodes Examined	136
multiple myeloma and Regional Nodes Positive	136
multiple myeloma and Summary Stage	125, 131
multiple myeloma and Tumor Size	98
multiple primaries.....	13-39
multiple primaries and Comments	176
multiple primaries and surgery of primary site.....	150
multiple primaries, reporting	4
multiple surgical procedures and surgery of primary site.....	150
multiple surgical procedures and Surgery of Primary Site – Narrative	145
multiple surgical procedures and Surgical Margins	152
multiple tumors and cT Element	104
multiple tumors and Narrative Primary Site	104, 114
multiple tumors and Narrative Staging	104, 114
multiple tumors and pT Element	114
multiple tumors and TNM staging, not coded.....	102, 104
multiple tumors in one organ, and Primary Site Code	73
mycosis fungoides and Tumor Size	98
myeloma, multiple and Regional Nodes Examined	136
myeloma, multiple and Regional Nodes Positive	136
myeloma, multiple and Summary Stage	125, 131
myeloma, multiple and Tumor Size	98
myeloproliferative malignancy, lymphoreticular process, Primary Site Code	75
name, "also known as".....	51
Name, Alias	51
name, first initial plus middle name.....	50
Name, Maiden	50
Name of Vendor	177
Name, Patient	49

INDEX

I-15

	<u>page(s)</u>
Name, Patient and changes/case deletion	5
Name, Patient and nonanalytic case reporting	10
name, physician's	48
Name Suffix	49
Name Suffix as new field	ii
Narrative Histology/Behavior/Grade	90
Narrative Primary Site	78
Narrative Primary Site and multiple tumors.....	104, 114
Narrative Remarks	176
Narrative Staging	139
Narrative Staging and multiple tumors	104, 114
Narrative Staging and site(s) of distant metastasis.....	111, 121
Narrative Staging as new field	iii
Narrative, Chemotherapy	165
Narrative, Hormone Therapy	168
Narrative, Immunotherapy	171
Narrative, Other Cancer-Directed Therapy	174
Narrative, Radiation Therapy	161
Narrative, Surgery of Primary Site	146
narrative, non cancer-directed surgery.....	146
National Cancer Registries Amendment Act	1
natural killer cell origin.....	iii
neck dissection and Scope of Regional Lymph Node Surgery	153
neoplasia, intraepithelial, case reportability.....	11, 83, 85
neoplasia, lobular and Behavior Code	85
neoplasia, lobular and Summary Stage	128
neuroblastoma, Primary Site Code	75
new codes, ICD-O-2, since 1995.....	79
nickname.....	51
no cancer-directed surgery and Scope of Regional Lymph Node Surgery	153
no cancer-directed surgery and Surgery of Primary Site -- Narrative	143
no cancer-directed surgery and Surgical Margins	152
No Cancer-Directed Surgery, Reason For	157
no primary tumor and Tumor Size	97
"no treatment" as treatment plan.....	141
nodule, tumor, coded in N Element.....	107, 117
nodule, tumor, coded in T Element.....	114
nodule, tumor, counted in Regional Nodes Examined	135
nodule, tumor, counted in Regional Nodes Positive	137
non cancer-directed surgery	142, 144-146
Non Cancer-Directed Surgery -- At This Facility	146
Non Cancer-Directed Surgery -- At This Facility as new field	iv

INDEX

I-16

	<u>page(s)</u>
Non Cancer-Directed Surgery -- Date Started	146
Non Cancer-Directed Surgery -- Date Started as new field.....	iv
Non Cancer-Directed Surgery -- Summary	145
Non Cancer-Directed Surgery -- Summary as new field	iv
non cancer-directed surgery and Surgery of Primary Site -- Narrative	146
non cancer-directed surgery narrative.....	146
"non cancer-directed treatment" defined	142
non-Hodgkin's lymphoma and Tumor Size	98
non-hospital case reporting.....	1
non-localized Summary Stage	131
non-Massachusetts residents, reporting	3
non-reportable cases for Massachusetts Cancer Registry	11, 83
nonanalytic case and Class of Case	92
nonanalytic case and Summary Stage	131, 132
nonanalytic cases, reporting requirements	10
nonmalignant tumor, Sequence Number	42, 44
"NOS" histology code	80-82
"NOS" subcategory, Primary Site Code	73, 74
"not applicable" and M Element.....	109, 111, 119, 121
"not applicable" and N element.....	108, 118
"not applicable" and Stage Grouping	112, 113, 122, 123
"not applicable" and T Element.....	105, 106, 115, 116
Nottingham grading and Grade Code	89
Number of Regional Lymph Nodes Removed	154
Number of Regional Lymph Nodes Removed -- At This Facility	154, Appendix D
Number of Regional Lymph Nodes Removed -- At This Facility as new field.....	iv
Number of Regional Lymph Nodes Removed -- Summary	154, Appendix D
Number of Regional Lymph Nodes Removed -- Summary as new field	iv
Number of Regional Lymph Nodes Removed and Regional Nodes Examined	135, 154
Number of Regional Lymph Nodes Removed and Regional Nodes Positive	137
occult lung cancer and TNM staging	105, 106, 113, 116, 123
occupation and industry	68-71
office, physician's, chemotherapy in	164
office, physician's, hormone therapy in	168
office, physician's, immunotherapy in	170
office, physician's, lymph nodes removed in.....	154
office, physician's, "other" therapy in.....	173
office, physician's, radiation in	160
office, physician's, surgery in.....	151
"open, assisted by endoscopy" and Surgical Approach	148
"open" Surgical Approach	147
Origin, Spanish/Hispanic	62-66

INDEX

I-17

	<u>page(s)</u>
other cancer-directed therapy	172-174
Other Cancer-Directed Therapy -- At This Facility	173
Other Cancer-Directed Therapy -- Date Started	174
Other Cancer-Directed Therapy -- Narrative	174
Other Cancer-Directed Therapy -- Summary	173
"other" treatment	172-174
outpatient Admission Date	47
outpatient Discharge Date	47
ovarian cystadenoma and Behavior Code	84
ovarian primary, bilateral, Laterality	75
ovary primary, residual tumor, and Surgical Margins	152
ovary, bilateral involvement, and single-vs-multiple primaries.....	18
overlapping lesion, Primary Site Code	73
oxygen, hyperbaric.....	172
Paget's disease of breast and intraductal carcinoma.....	19
paired organs.....	76-77, Appendix B
paired organs and Laterality	75
paired organs and single-vs-multiple primaries.....	18
paired primary sites.....	76-77, Appendix B
paired primary sites and Laterality	75
palliative surgery.....	144
"palpable", lymph nodes, and Summary Stage	132
palpitation and Confirmation Method	100
papillary carcinomas of skin C44., as non-reportable cases.....	11, 83
paracentesis and non cancer-directed surgery.....	144
pathologic confirmation of diagnosis, and case reportability.....	11
pathologic M Element.....	119-121
pathologic N Element.....	117-118
pathologic Stage Grouping.....	122-123
pathologic staging, TNM.....	102-103, 114-123
pathologic T Element.....	114-116
pathology report terminology and case reportability.....	12
pathology-only cases, reportability.....	40
Patient First Name	50
Patient Last Name	49
Patient Middle Name	50
Patient Name	49
Patient Name, Suffix	49
patient surname.....	49
Pediatric Stage	132-133
Pediatric Stage as new field.....	iii
Pediatric Staging System	134

INDEX

I-18

	<u>page(s)</u>
Pediatric Staging System as new field	iii
penis, skin of, case reportability	11, 83
PET results and Grade Code	88
Physician Name, Managing	48
physician's office, chemotherapy in	164
physician's office, hormone therapy in	168
physician's office, immunotherapy in	170
physician's office, lymph nodes removed in	154
physician's office, "other" therapy in	173
physician's office, radiation therapy in	160
physician's office, surgery in	151
physician's office, treatment in, and "at this facility" fields	143
physician, managing	48
PIN III and Behavior Code	85
PIN III, case reportability	11, 83, 85
Place of Birth	54, Appendix A
Place of Birth and Race	60
Place of Death	176, Appendix A
Place of Death and living patient	176
Place of Death and new code	v
Place of Diagnosis	101
plan, treatment	141
pM	119-121
pM88	119, 121
pMX	119, 121
pN	117-118
pN and Regional Nodes Examined	135
pN and Regional Nodes Positive	137
pN88	118
pNX	117, 118
polyposis, familial, and Primary Site Code	75
polyposis, familial, and Tumor Size	97
positron emission tomography and Grade Code	88
"possible" and case reportability	12
"possible" and Summary Stage	127
Postal Code at Diagnosis	57
PPO, Primary Payer at Diagnosis	46
precancerous melanosis and Behavior Code	85
precancerous melanosis and Summary Stage	128
Prednisone + MOPP or COPP	166
Prednisone with chemotherapy	166
"predominantly" and Histologic Type Code	81

INDEX

I-19

	<u>page(s)</u>
prefixes, TNM staging, not coded	102
preoperative chemotherapy and TNM staging.....	103
preoperative radiation and TNM staging	103
preoperative radiation and Tumor Size	94
preoperative treatment and Regional Nodes Examined	136
preoperative treatment and Regional Nodes Positive	136
prepuce, skin of, case reportability.....	11, 83
"presumed" and case reportability.....	12
"presumed" and Summary Stage	127
Primary Payer at Diagnosis	46
Primary Payer at Diagnosis as new field	ii
Primary Site and case reportability	11, 83
Primary Site Code	73-75
Primary Site Code and change in laryngopharynx	iii
Primary Site Code and nonanalytic case reporting	10
primary site codes considered a single site	14, 16
primary site groupings for single-vs-multiple primaries.....	14, 16
Primary Site, Narrative	78
Primary Site Narrative and Laterality	78
Primary Site Narrative and multiple tumors.....	104, 114
primary-vs-metastatic lesions	12
primary-vs-metastatic site.....	74, 78
priority of codes, surgery of primary site	149
"probable" and case reportability.....	12
"probable" and Summary Stage	127
prophylactic radiation.....	158
prostate cancer and Confirmation Method	100
prostate cancer and endocrine surgery/radiation.....	167
prostate cancer and Grade Code	89
prostate cancer and Summary Stage time period	125
prostate, intraepithelial neoplasia of, and Behavior Code	85
prostate, intraepithelial neoplasia of, case reportability	11, 83, 85
prostate, transurethral resection and Tumor Size	98
prostatic intraepithelial neoplasia and Behavior Code	85
prostatic intraepithelial neoplasia and Summary Stage	128
protocol number, chemotherapy	162, 165
province at diagnosis (Canada)	57-58
PSA test and Confirmation Method	100
pStage Grouping	122-123
pStage Grouping 88.....	122, 123
pStage Grouping 99.....	122, 123
pT.....	114-116

INDEX

I-20

	<u>page(s)</u>
pT88.....	115
pTNM	102-103, 114-123
pTX	115
"questionable" and case reportability	12
"questionable" and Summary Stage	127
Queyrat's erythroplasia and Behavior Code	85
Queyrat's erythroplasia and Summary Stage	128
Race	60-61
Race and Birthplace	60
Race and nonanalytic case reporting	10
race, mixed	60
Radiation/Surgery Sequence	161
radiation therapy.....	158-161
Radiation Therapy -- At This Facility	160
Radiation Therapy -- At This Facility having new codes.....	v
Radiation Therapy -- Date Started	161
Radiation Therapy -- Narrative	161
Radiation Therapy -- Summary	160
Radiation Therapy -- Summary having new codes.....	v
radiation therapy and cancer-directed surgery	161
radiation therapy, external source.....	159
radiation therapy, internal source.....	159
radiation therapy, radioactive substances for	158
radiation, beam, types of	159
radiation, curative.....	158
radiation, hormonal.....	158
radiation, prophylactic.....	158
radioactive implants.....	159
radioactive seed implants	159
radioactive substances for radiation therapy	158
radiography and Confirmation Method	100
radioisotope, types of.....	159
Rappaport classification for lymphoma, Histologic Type Code	79
re-excision and cancer-directed surgery.....	147
Reason For No Cancer-Directed Surgery	157
"reasonable clinical certainty" of primary site, and TNM staging.....	102
Reconstruction/Restoration -- First Course	156, Appendix D
Reconstruction/Restoration -- First Course as new field	v
rectum, cancer of, and Tumor Size	97
recurrent cancer prefix and TNM staging, not coded.....	103
reference date, Massachusetts Cancer Registry (January 1, 1982)	1, 3
Regional Lymph Node Surgery, Scope of	153

INDEX

I-21

	<u>page(s)</u>
Regional Lymph Nodes Removed, Number of	154
Regional Nodes Examined	135-136
Regional Nodes Examined and Number of Regional Lymph Nodes Removed	154
Regional Nodes Examined as new field	iii
Regional Nodes Positive	137-138
Regional Nodes Positive as new field	iii
"regional" and Summary Stage	126
regional Summary Stage	130-131
regulations, confidentiality	2
regulations, Massachusetts Cancer Registry	1, 2
relapse and subsequent treatment	141, 142
Remarks, Narrative	176
replacement therapy, hormone	167
reportability of cases to the Massachusetts Cancer Registry	83
"reportable diagnosis"	11, 83
Reporting Facility Code and nonanalytic case reporting	10
Reporting Facility Name and changes/case deletion	5
reporting methods for Massachusetts Cancer Registry.....	4
reporting requirements for Massachusetts Cancer Registry.....	1, 3, 10, 11, 12, 13, 40
Reporting Source	101
resection, en bloc, of primary and regional tissues, and surgery of primary site	149, 155
resection, transurethral, and non cancer-directed surgery	144
resection, transurethral and Tumor Size	98
residual tumor and cancer-directed surgery	147
residual tumor and ovary primary, Surgical Margins	152
residual tumor and TNM staging, not coded.....	103
residual tumor and Tumor Size	94
Restoration/Reconstruction -- First Course	156, Appendix D
reticuloendothelial system and Primary Site Code	75
reticuloendotheliosis and Regional Nodes Examined	136
reticuloendotheliosis and Regional Nodes Positive	136
reticuloendotheliosis and Summary Stage	125, 131
reticuloendotheliosis and Tumor Size	98
retinoblastoma, bilateral, and Laterality	75
retinoblastoma, bilateral, and single-vs-multiple primaries	18
retroareolar breast tumor, Primary Site Code	75
risk factors and Stage Grouping, and Comments/Narrative Remarks	112, 122
risk factors and Stage Grouping, and Narrative Staging	112, 122
ROADS Manual, as reference.....	9
rTNM.....	103
"rules out" and case reportability.....	12
"rules out" and Summary Stage	127

INDEX

I-22

	<u>page(s)</u>
"S", lymphoma suffix, and TNM staging, not collected	113, 123
"Saint", abbreviating in Last Name	49
sarcoma, Kaposi's, and Tumor Size	98
sarcoma, Kaposi's, and single-vs-multiple primaries	19
satellite nodules and Summary Stage	129
satellite tumors and Summary Stage	129
SBR grading and Grade Code	89
Scarff Bloom-Richardson grading and Grade Code	89
scleral invasion and TNM staging, not coded	103
Scope of Regional Lymph Node Surgery	153
Scope of Regional Lymph Node Surgery and no cancer-directed surgery	153
Scope of Regional Lymph Node Surgery -- At This Facility	153, Appendix D
Scope of Regional Lymph Node Surgery -- At This Facility as new field	iv
Scope of Regional Lymph Node Surgery -- Summary	153, Appendix D
Scope of Regional Lymph Node Surgery -- Summary as new field	iv
scrotum, skin of, case reportability	11, 83
secondary therapy	141
seed implants, radioactive	159
SEER General Summary Stage	125-132
<i>SEER Summary Staging Guide</i> as reference	8
<i>Self-Instructional Manuals for Tumor Registrars</i> (SEER)	9
"Senior" as generation identifier	49
Sequence Number	42-44
Sequence Number and nonanalytic case reporting	10
Sequence Number having new codes	ii
serum markers and Stage Grouping, and Comments/Narrative Remarks	112, 122
serum markers and Stage Grouping, and Narrative Staging	112, 122
Sex , patient's	59
Sex , patient's, and nonanalytic case reporting	10
"shotty", lymph nodes, and Summary Stage	132
simultaneous diagnoses	15
simultaneous diagnoses and Sequence Number	43
single-vs-multiple primaries	13-39
single-vs-multiple primaries, Histologic Type Code	80-82
"site difference" for single-vs-multiple primaries	14
site groupings considered a single site	14, 16
site(s) of distant metastasis and Narrative Staging	111, 121
site(s) of distant metastasis and TNM staging, not coded	111, 121
site-specific morphologies and Primary Site Code	74
site/histology combination, unusual, and Comments	176
site/histology combinations and case reportability	11, 83
Size of Tumor	94-98

INDEX

I-23

	<u>page(s)</u>
skin C44., epithelial carcinomas, as non-reportable cases	11, 83
skin C44., malignant neoplasms, NOS, as non-reportable cases.....	11, 83
skin of genital sites, case reportability.....	11, 83
skin, Kaposi's sarcoma, and single-vs-multiple primaries.....	19
skin, melanoma of, and "site differences"	14
Smoking Status	67
Social Security Number	54
Social Security Number and changes/case deletion	5
Social Security Number and nonanalytic case reporting.....	10
software vendor, name	177
Spanish surname.....	62-66
Spanish/Hispanic Origin	62-66
Spanish/Hispanic Origin and Birthplace	62
Spanish/Hispanic Origin having new code definition.....	ii
specimen size and Tumor Size	95
spleen, lymphoma involvement, and TNM staging.....	113, 123
"spring" and Date of Diagnosis	91
squamous cell carcinoma, microinvasive, and Behavior Code	86
squamous cell carcinoma, microinvasive, and Summary Stage	129
squamous cell carcinomas of skin C44., as non-reportable cases	11, 83
"Sr" (Senior) as generation identifier	49
"St", as abbreviation for Saint in Last Name	49
"Stage 0" and Behavior Code	85
"Stage 0" and Summary Stage	128
"Stage X"	113, 123
Staging Narrative	139
Staging Narrative and multiple tumors	104, 114
Staging Narrative and site(s) of distant metastasis.....	111, 121
start dates, treatment.....	143
State at Diagnosis	57-58
State at Diagnosis having new code definitions	ii
steroid therapy.....	166-169
stomach cancer and Tumor Size	97
Street Address at Diagnosis	55-56
subareolar breast tumor, Primary Site Code	75
subsequent therapy	141
Suffix, Name	49
suffixes, TNM staging, not coded.....	102
"suggests" and case reportability	12
"suggests" and Summary Stage	127
Summary Stage	125-132
<i>Summary Staging Guide</i> as reference	8

INDEX

I-24

	<u>page(s)</u>
summary, treatment, fields	143
Surgery of Other Regional Sites, Distant Sites or Distant Lymph Nodes	155
Surgery of Other Regional Sites, Distant Sites or Distant Lymph Nodes -- Summary	155, Appendix D
Surgery of Other Regional Sites, Distant Sites or Distant Lymph Nodes -- Summary as new field v	
Surgery of Other Regional Sites, Distant Sites or Distant Lymph Nodes -- At This Facility	155, Appendix D
Surgery of Other Regional Sites, Distant Sites or Distant Lymph Nodes -- At This Facility as new field	v
surgery of primary site	149-151
Surgery of Primary Site -- At This Facility	151, Appendix D
Surgery of Primary Site -- At This Facility and new codes	iv
Surgery of Primary Site -- Date Started	151
Surgery of Primary Site -- Narrative	151
Surgery of Primary Site -- Narrative and multiple surgical procedures	145
Surgery of Primary Site -- Narrative and no cancer directed surgery.....	143, 151
Surgery of Primary Site -- Narrative and non cancer-directed surgery.....	146, 151
Surgery of Primary Site -- Narrative to include non-cancer directed surgery	iv
Surgery of Primary Site -- Summary	151, Appendix D
Surgery of Primary Site -- Summary and new codes.....	iv
Surgery of Primary Site -- Summary and Surgical Approach	147
surgery of primary site and multiple primaries.....	150
surgery of primary site and multiple procedures.....	150
Surgery of Primary Site and Number of Regional Lymph Nodes Removed	154
surgery of primary site, code priority	150
Surgical Approach	147-148, Appendix D
Surgical Approach and Surgery of Primary Site -- Summary	147
Surgical Approach as new field	iv
Surgical Margins	152, Appendix D
Surgical Margins and multiple procedures	152
Surgical Margins and no cancer-directed surgery	152
Surgical Margins as new field	iv
Surgical Margins for residual ovarian tumor.....	152
surname, patient's	49
surname, Spanish/Hispanic	62-66
"suspect" and case reportability	12
"suspect" and Summary Stage	127
"suspected" and case reportability	12
"suspected" and Summary Stage	127
"suspicious" and case reportability	12
"suspicious" and Summary Stage	127
suspicious cytology and case reportability.....	12

INDEX

I-25

	<u>page(s)</u>
synchronous diagnoses.....	15
systematic symptoms, lymphoma, and TNM staging, not collected.....	113, 123
systemic disease, Summary Stage	125, 131
T0 and Tumor Size	97
teletherapy, radiation therapy	159
terminology in medical record for non-reportable cases	12
terminology in medical record for reportable cases	12
thoracentesis and non cancer-directed surgery	144
thyroid cancer and hormone therapy.....	167
thyroid-stimulating hormone	167
time period and first course of treatment.....	141, 142
time periods for Summary Stage	125
TNM Edition Number	124
TNM Edition Number as new field	iii
TNM staging.....	102-124
TNM staging books as references.....	8
Tobacco History	67
Tobacco History as new name for Smoking Status	ii
topography code.....	73-75
Town at Diagnosis	56
transurethral resection and non cancer-directed surgery	144
transurethral resection and Tumor Size	98
treatment "at this facility" fields	143
"treatment, first course" defined.....	141-142
treatment narratives	143
treatment plan	141
treatment start dates.....	143
treatment summary fields	143
treatment, failed	142
TSH (thyroid-stimulating hormone).....	167
tumor embolization.....	172
tumor nodule coded in N Element.....	107, 117
tumor nodule coded in T Element.....	114
tumor nodule counted in Regional Nodes Examined	135
tumor nodule counted in Regional Nodes Positive	137
Tumor Size	94-98
TUR and non cancer-directed surgery.....	144
TUR and Tumor Size	98
TURB and Tumor Size	98
TURP and Tumor Size	98
type of business/usual industry	68-71
Type of Reporting Source	101
Type of Reporting Source and nonanalytic case reporting	10

INDEX

I-26

	<u>page(s)</u>
Type of Reporting Source as new name for Place of Diagnosis	iii
"typical for" and case reportability.....	12
"typical for" and Summary Stage	127
"typical of" and case reportability.....	12
"typical of" and Summary Stage	127
ultrasound and Confirmation Method	100
uncertain behavior, Sequence Number	42, 44
uncertain malignancy cases, reportability.....	11, 83
uninsured patient, Primary Payer at Diagnosis	46
unknown primary site.....	74
unknown primary site and Grade/Differentiation/Cell Origin Code	86, 87
unknown primary site and Laterality	75
unknown primary site and Regional Nodes Examined	136
unknown primary site and Regional Nodes Positive	136
unknown primary site and Summary Stage	125, 132
unknown primary site and TNM staging.....	102
unknown primary site and Tumor Size	98
"usual industry" defined.....	68, 70
"usual occupation" defined.....	68, 70
"usual residence" address at diagnosis defined.....	55
vagina, intraepithelial neoplasia of, case reportability.....	11, 83
vagina, skin of, case reportability.....	11, 83
VAIN III, case reportability.....	11, 83
Vendor Name / Version Number	177
Vendor Name / Version Number as new field.....	vi
vendors and case reporting.....	4
venous invasion and TNM staging, not coded.....	103
"very close to" and case reportability.....	12
"very close to" and Summary Stage	127
VIN III, case reportability.....	11, 83
"visible swelling", lymph nodes, and Summary Stage	132
visualization and Confirmation Method	100
Vital Status	175
vulva, intraepithelial neoplasia of, case reportability.....	11, 83
vulva, skin of, case reportability.....	11, 83
Waldenstrom's macroglobulinemia and Confirmation Method	100
Welfare, Primary Payer at Diagnosis	46
wide excision and cancer-directed surgery.....	147
"widespread" and Tumor Size	97
Wilms's tumor, bilateral, and single-vs-multiple primaries.....	18
Wilms's tumor, Laterality	75
"winter" and Date of Diagnosis	91

INDEX

I-27

	<u>page(s)</u>
"with features of" and Histologic Type Code	81
"with foci of" and Histologic Type Code	81
Working Formulation for lymphoma, Histologic Type Code	79
Working Formulation terminology for lymphomas, and Grade Code	87
"worrisome" and case reportability	12
"worrisome" and Summary Stage	127
Year First Seen for This Primary	45
Year First Seen for This Primary and Accession Number	45
Year First Seen for This Primary and diagnosis year	45
Year First Seen for This Primary as new field.....	ii
year of diagnosis and Age at Diagnosis	53
year of diagnosis and Year First Seen for This Primary	45
yTNM	103
Zip Code at Diagnosis	57
ZIP Code at Diagnosis having new code definitions	ii
ZIP Code reference books.....	9